| Name | Symbol | Market | Type |
|---|---|---|---|
| Ve Bionic Etf | LSE:CYBG | London | Exchange Traded Fund |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.012 | -0.07% | 17.055 | 16.962 | 17.14 | 0 | 16:35:28 |
Virgin Money UK PLC Transaction in Own Shares and CDIs
06/12/2022 7:00am
UK Regulatory (RNS & others)
Ve Bionic Etf (LSE:CYBG)
Historical Stock Chart
From Jun 2022 to Jun 2023
TIDMVMUK TIDM91XR
RNS Number : 6686I
Virgin Money UK PLC
06 December 2022
Virgin Money UK PLC
LEI: 213800ZK9VGCYYR6O495
ISIN: GB00BD6GN030
6 December 2022
Virgin Money UK PLC (the "Company")
Transaction in Own Shares and CDIs
The Company announces that on 5 December 2022 it had purchased a total of (a) 1,255,300 of its ordinary shares of GBP0.10 each (the "ordinary shares") on the London Stock Exchange, Chi-X Europe and/or BATS Europe through the Company's broker Citigroup Global Markets Limited and (b) 644,298 CHESS Depositary Interests ("CDIs"), each representing one ordinary share, on the Australian Securities Exchange through the Company's broker Citigroup Global Markets Australia Pty Limited, in each case as detailed below. The repurchased ordinary shares (including the CDIs, once transmuted into ordinary shares) will be cancelled.
London Chi-X Europe BATS Europe Australian
Stock Exchange Securities
Exchange
Number of ordinary
shares/CDIs purchased
on 05 December 2022 687,000 244,300 324,000 644,298
---------------- ------------- ------------ ------------
Highest price paid GBP1.8090 GBP1.8085 GBP1.8085 A$3.2100
(per ordinary share/CDI)
on 05 December 2022
---------------- ------------- ------------ ------------
Lowest price paid GBP1.7745 GBP1.7745 GBP1.7740 A$3.1500
(per ordinary share/CDI)
on 05 December 2022
---------------- ------------- ------------ ------------
Volume weighted GBP1.7936 GBP1.7934 GBP1.7934 A$3.1855
average price paid
(per ordinary share/CDI)
---------------- ------------- ------------ ------------
The purchases form part of (i) the Company's share buyback programme announced on 30 June 2022 (the "Initial Buyback") and (ii) the Company's extended share buyback programme announced on 21 November 2022 (the "Extended Buyback"). The Initial Buyback and Extended Buyback will be effected within the scope of the authority conferred on the Company at its February 2022 Annual General Meeting. The Initial Buyback start date was 30 June 2022 and end date is 17 December 2022. The Extended Buyback start date was 21 November 2022 and in the case of Shares bought back in the UK the end date is 2 May 2023 and, in the case of CDIs bought back in Australia, the end date is 2 May 2023 subject to approval by shareholders within the scope of the authority to be sought at the Company's 2023 Annual General Meeting.
The total number of ordinary shares and CDIs purchased up to and including the prior announcement was 60,442,052. As such, the Company has now bought back 62,341,650 ordinary shares and CDIs (in aggregate). In connection with the Initial Buyback, the Company intends to repurchase up to GBP75 million of ordinary shares and CDIs (in aggregate) and in connection with the Extended Buyback the Company intends to repurchase up to GBP50 million of ordinary shares and CDIs (in aggregate).
Following settlement of the above purchases and cancellation of the purchased ordinary shares and CDIs, the Company's total number of ordinary shares in issue shall be 1,380,634,526.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, to view the detailed breakdown of individual trades made by Citigroup Global Markets Limited on behalf of the Company as part of the share buyback programme please follow this link.
http://www.rns-pdf.londonstockexchange.com/rns/6686I_1-2022-12-5.pdf
This announcement does not constitute, or form part of, an offer or solicitation of an offer for securities in any jurisdiction.
Announcement authorised for release by Lorna McMillan, Group Company Secretary.
For further information, please contact:
Investors and Analysts
Richard Smith +44 7483 399 303
------------------------------------
Head of Investor Relations richard.smith@virginmoneyukplc.com
------------------------------------
Amil Nathwani +44 7702 100 398
------------------------------------
Senior Manager, Investor Relations amil.nathwani@virginmoneyukplc.com
------------------------------------
Martin Pollard +44 7894 814 195
------------------------------------
Senior Manager, Investor Relations martin.pollard@virginmoneyukplc.com
------------------------------------
Company Secretary
------------------------------------
Lorna McMillan 07834 585436
------------------------------------
Group Company Secretary lorna.mcmillan@virginmoneyukplc.com
------------------------------------
Media Relations
------------------------------------
Press Office 0800 066 5998
------------------------------------
press.office@virginmoneyukplc.com
------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
POSFSSFAIEESEFE
(END) Dow Jones Newswires
December 06, 2022 02:00 ET (07:00 GMT)
1 Year Ve Bionic Etf Chart |
1 Month Ve Bionic Etf Chart |